A study for the prophylaxis of venous thromboembolic disease and the treatment of deep vein thrombosis, as well as hemorrhagic or thrombotic complications using enoxaparin sodium biosimilar (Inhixa)
Latest Information Update: 08 Aug 2021
At a glance
- Drugs Enoxaparin sodium (Primary) ; Heparin; Vitamin K antagonists
- Indications Deep vein thrombosis; Haemorrhage; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association.